Dr. Liu’s research centers on bacterial pathogenesis at the host–pathogen–microbiota interface, with two complementary goals: (1) how pathogens sense niche-specific cues and remodel host responses to drive infection, and (2) to translate mechanistic insights into microbiome-informed, non-antibiotic anti-infective strategies. He primarily investigates Vibrio cholerae, enterohemorrhagic E. coli (EHEC), and uropathogenic E. coli (UPEC), integrating bacterial genetics, comparative genomics and transcriptomics, host immunology, and in vivo infection models.
Representative contributions include: uncovering how V. cholerae senses hypoxic signals in the small intestine and how chitosan oligosaccharides inhibit the ChsR-mediated virulence pathway, enabling a microgel-based therapeutic approach; defining that microbiota-derived metabolites (e.g., riboflavin, L-malate, succinate) are transduced via specific regulators and post-translational modifications (e.g., lysine succinylation of PurR) to potentiate EHEC T3SS expression and intestinal colonization; and revealing how UPEC secretes nucleoside diphosphate kinase to evade inflammasome-mediated surveillance and suppress host pyroptosis, thereby facilitating intracellular growth and IBC formation. He also co-developed a biomimetic, FimH-targeting microgel that competitively captures adherent-invasive E. coli to mitigate intestinal inflammation, offering an antibiotic-sparing strategy for IBD.
Research and academic interests:
(1)Host–pa
Dr. Liu’s research centers on bacterial pathogenesis at the host–pathogen–microbiota interface, with two complementary goals: (1) how pathogens sense niche-specific cues and remodel host responses to drive infection, and (2) to translate mechanistic insights into microbiome-informed, non-antibiotic anti-infective strategies. He primarily investigates Vibrio cholerae, enterohemorrhagic E. coli (EHEC), and uropathogenic E. coli (UPEC), integrating bacterial genetics, comparative genomics and transcriptomics, host immunology, and in vivo infection models.
Representative contributions include: uncovering how V. cholerae senses hypoxic signals in the small intestine and how chitosan oligosaccharides inhibit the ChsR-mediated virulence pathway, enabling a microgel-based therapeutic approach; defining that microbiota-derived metabolites (e.g., riboflavin, L-malate, succinate) are transduced via specific regulators and post-translational modifications (e.g., lysine succinylation of PurR) to potentiate EHEC T3SS expression and intestinal colonization; and revealing how UPEC secretes nucleoside diphosphate kinase to evade inflammasome-mediated surveillance and suppress host pyroptosis, thereby facilitating intracellular growth and IBC formation. He also co-developed a biomimetic, FimH-targeting microgel that competitively captures adherent-invasive E. coli to mitigate intestinal inflammation, offering an antibiotic-sparing strategy for IBD.
Research and academic interests:
(1)Host–pa